All In Biotech

Drug Trial Radar · NCT01137682

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly

Last checked: Nov 20, 2026Latest source record: Apr 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

198

Actual

Start

Jul 19, 2010

Primary completion

Jan 22, 2013

Study completion Feb 28, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 4, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.

Conditions

  • Acromegaly

Interventions

  • PasireotideDrug

    * Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or * Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks

  • octreotide LAR 30mgDrug

    In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization

  • lanreotide ATG 120mgDrug

    In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.Time frame: At 24 weeks

Locations

60 sites in 18 countries. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan

  • Oregon Health & Science University

    Portland, Oregon

  • University of Texas Southwestern Medical Center Division of Hematology/Oncolog

    Dallas, Texas

  • Swedish Neuroscience Institute 550 17th Avenue, Suite 500

    Seattle, Washington

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Edegem, Antwerpen, Belgium

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    São Luís, Maranhão, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Joinville, Santa Catarina, Brazil

  • Novartis Investigative Site

    Botucatu, São Paulo, Brazil

  • Novartis Investigative Site

    Campinas, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Sherbrooke, Quebec, Canada

  • Novartis Investigative Site

    Bogotá, Colombia

  • Novartis Investigative Site

    Cali, Colombia

  • Novartis Investigative Site

    Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Saint Herblain - Nantes, France

  • Novartis Investigative Site

    Bron, Cedex, France

  • Novartis Investigative Site

    Toulouse, Cedex 9, France

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Petah Tikva, Israel

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Messina, ME, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.